Valganciclovir Sandoz 450 mg Noruega - noruec - Statens legemiddelverk

valganciclovir sandoz 450 mg

sandoz - københavn - valganciklovirhydroklorid - tablett, filmdrasjert - 450 mg

Zanipress 10 mg / 10 mg Noruega - noruec - Statens legemiddelverk

zanipress 10 mg / 10 mg

recordati ireland limited - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg / 10 mg

Zanipress 20 mg / 10 mg Noruega - noruec - Statens legemiddelverk

zanipress 20 mg / 10 mg

recordati ireland limited - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg / 10 mg

Zoloft 100 mg Noruega - noruec - Statens legemiddelverk

zoloft 100 mg

farmagon - sertralinhydroklorid - tablett, filmdrasjert - 100 mg

Iclusig 15 mg Noruega - noruec - Statens legemiddelverk

iclusig 15 mg

orifarm as - ponatinibhydroklorid - tablett, filmdrasjert - 15 mg

Gastrografin 0.1 g/ ml / 0.66 g/ ml Noruega - noruec - Statens legemiddelverk

gastrografin 0.1 g/ ml / 0.66 g/ ml

2care4 aps - natriumamidotrizoat / megluminamidotrizoat - mikstur/rektalvæske, oppløsning - 0.1 g/ ml / 0.66 g/ ml

Bortezomib Viatris 3.5 mg Noruega - noruec - Statens legemiddelverk

bortezomib viatris 3.5 mg

viatris limited - bortezomibmannitolboronat - pulver til injeksjonsvæske, oppløsning - 3.5 mg

Eprinex vet. 5 mg/ ml Noruega - noruec - Statens legemiddelverk

eprinex vet. 5 mg/ ml

boehringer ingelheim animal health nordics a/s - eprinomektin - påhellingsvæske, oppløsning - 5 mg/ ml

Dasatinib Accordpharma Unió Europea - noruec - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Scemblix Unió Europea - noruec - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - leukemi, myelogen, kronisk, bcr-abl positiv - antineoplastiske midler - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.